Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group

NCT02172872 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT02172872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02172872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 3
Overall status
Unknown status
Start date
November 28, 2014
Completion date
December 31, 2023
Enrollment
606 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)